Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Sep 2021: Trial registered, NCT05039632
  2. 8 May 2023: Trial started, NCT05039632

The trials

NCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
40 planned
Started
8 May 2023
Primary completion
1 Feb 2028
Arms
Cohort I (NBTXR3, Abscopal, Anti PD-1 / PD-L1, Cohort II (NBTXR3, RadScopal, Anti PD-1 / PD-L1
Results
None posted
  1. 9 Sep 2021: Trial registered
  2. 8 May 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.